Zolbetuximab Plus mFOLFOX6 Scores in Gastric Cancer
Zolbetuximab added to mFOLFOX6 improved the progression-free survival (PFS) and overall survival...
Read MoreJan 27, 2023
Zolbetuximab added to mFOLFOX6 improved the progression-free survival (PFS) and overall survival...
Read MoreJan 20, 2023
Single fraction radiation therapy (RT) outperformed best supportive care in reducing hepatic pain...
Read MoreJan 13, 2023
The Gastrointestinal Cancers Symposium will focus on multidisciplinary care that will highlight...
Read MoreJan 13, 2023
Thursday, January 19 Time: 12:15 PM – 1:00 PM Location: Posters, Exhibits, and Food Room...
Read MoreJan 13, 2023
Thursday, January 19, 2023 7:00 AM-8:00 AM Complimentary Continental Breakfast 7:00 AM-5:45 PM...
Read MoreJan 13, 2023
Therapy with atezolizumab (atezo) plus bevacizumab (bev) in systemic treatment (tx)-naive patients...
Read MoreJan 13, 2023
Atezolizumab plus bevacizumab (A+B) is the new standard of care for first-line treatment of...
Read MoreJan 13, 2023
In the treatment of hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) based...
Read MoreJan 13, 2023
Hepatocellular carcinoma (HCC) is the most rapidly expanding cause of cancer-related mortality in...
Read MoreDec 21, 2022
Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...
Read MoreDec 21, 2022
The ACR 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly.
Read MoreDec 19, 2022
Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical...
Read MoreDec 19, 2022
The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...
Read MoreDec 19, 2022
Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...
Read MoreDec 19, 2022
A new, real-world study using more than 2 years of EMRs shows that patients with chronic...
Read MoreDec 19, 2022
A quiz based on the latest lung cancer news and studies from SOHO.
Read More